WTiNT is under clinical development by Eutilex and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect WTiNT’s likelihood of approval (LoA) and phase transition for Glioblastoma Multiforme (GBM) took place on 09 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
In addition, the same event on 09 Aug 2022 increased WTiNT’s Phase Transition Success Rate (PTSR) for Solid Tumor.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their WTiNT Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
WTiNT is under development for the treatment of recurrent solid tumors such as glioblastoma. The therapeutic candidate constitutes autologous Wilms tumor protein 1 (WT1)-specific CD8 positive T cells. It acts by targeting tumor cells expressing WT1. It is based on 4-1 BB CTL Adoptive T cell therapy. It was also under development for the treatment of leukemia. It is administered through intravenous route.
Eutilex Co. Ltd., a clinical-stage biopharmaceutical company that develops immunotherapy technology, anti tumor T cell therapy and antibody therapeutics, and other technology products. The company is headquartered in Republic of Korea (South Korea).
Quick View WTiNT LOA Data
|Highest Development Stage|